TipRanks
Celldex Therapeutics Inc (DE:TCE2)
FRANKFURT:TCE2
Germany Market
TCE2
Celldex
RESEARCH TOOLSreports

Celldex (TCE2) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

TCE2 Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Celldex
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TCE2 Stock 12 Month Forecast

Average Price Target

€53.08
▲(58.35% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Celldex in the last 3 months. The average price target is €53.08 with a high forecast of €86.31 and a low forecast of €32.80. The average price target represents a 58.35% change from the last price of €33.52.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","52":"€52","87":"€87","34.5":"€34.5","69.5":"€69.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86.306,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€86.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.07819,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€53.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.79628,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,34.5,52,69.5,87],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.61,37.66353846153846,41.717076923076924,45.77061538461538,49.82415384615385,53.87769230769231,57.931230769230766,61.98476923076923,66.03830769230768,70.09184615384615,74.14538461538461,78.19892307692308,82.25246153846153,{"y":86.306,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.61,35.107553076923075,36.60510615384615,38.102659230769234,39.60021230769231,41.097765384615386,42.59531846153846,44.09287153846154,45.59042461538461,47.08797769230769,48.58553076923077,50.08308384615384,51.58063692307692,{"y":53.07819,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.61,33.547406153846154,33.48481230769231,33.42221846153846,33.35962461538462,33.29703076923077,33.23443692307693,33.171843076923075,33.10924923076923,33.046655384615384,32.98406153846154,32.921467692307694,32.85887384615385,{"y":32.79628,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.56,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.95,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.61,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€86.31Average Price Target€53.08Lowest Price Target€32.80
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:TCE2
Judah Frommer
Morgan Stanley
Morgan Stanley
€39.7→€43.15
Buy
28.74%
Upside
Assigned
09/10/26
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Celldex (CLDX)
Jefferies Analyst forecast on DE:TCE2
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€58.69
Buy
75.08%
Upside
Reiterated
08/07/26
Celldex (CLDX) Gets a Buy from Jefferies
LifeSci Capital Analyst forecast on DE:TCE2
Sam Slutsky
LifeSci Capital
LifeSci Capital
€48.33
Buy
44.19%
Upside
Reiterated
08/07/26
Barzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target
Barclays Analyst forecast on DE:TCE2
Etzer Darout
Barclays
Barclays
€41.43→€45.74
Buy
36.46%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Buy Rating on Celldex (CLDX)
H.C. Wainwright Analyst forecast on DE:TCE2
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€36.25
Buy
8.14%
Upside
Reiterated
08/07/26
Celldex: Barzo Franchise Momentum and Upcoming Catalysts Support Buy Rating with Unchanged $42 Price Target
Goldman Sachs Analyst forecast on DE:TCE2
Richard Law CFA
Goldman Sachs
Goldman Sachs
€29.34→€32.8
Hold
-2.16%
Downside
Reiterated
08/07/26
Goldman Sachs Reaffirms Their Hold Rating on Celldex (CLDX)
Canaccord Genuity Analyst forecast on DE:TCE2
Edward Nash
Canaccord Genuity
Canaccord Genuity
€51.78
Buy
54.49%
Upside
Reiterated
08/06/26
Celldex: Buy Rating Reaffirmed as Strong 2Q26 Results, Robust Pipeline Support Unchanged $60 Price Target
Guggenheim Analyst forecast on DE:TCE2
Yatin Suneja
Guggenheim
Guggenheim
€86.31
Buy
157.48%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (NASDAQ: XFOR), Celldex (NASDAQ: CLDX) and Climb Bio (NASDAQ: CLYM)
Wells Fargo Analyst forecast on DE:TCE2
Derek Archila
Wells Fargo
Wells Fargo
€6.04→€62.14
Buy
85.38%
Upside
Reiterated
08/06/26
Wells Fargo Reaffirms Their Buy Rating on Celldex (CLDX)
Cantor Fitzgerald Analyst forecast on DE:TCE2
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€52.65
Buy
57.06%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS) and Celldex (NASDAQ: CLDX)
Leerink Partners Analyst forecast on DE:TCE2
Thomas Smith
Leerink Partners
Leerink Partners
€67.32→€60.41
Buy
80.23%
Upside
Reiterated
07/22/26
Celldex price target lowered to $70 from $78 at LeerinkCelldex price target lowered to $70 from $78 at Leerink
Stifel Nicolaus Analyst forecast on DE:TCE2
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€58.69
Buy
75.08%
Upside
Reiterated
07/22/26
Analysts Conflicted on These Healthcare Names: 10x Genomics (NASDAQ: TXG), Celldex (NASDAQ: CLDX) and MaxCyte (NASDAQ: MXCT)
UBS Analyst forecast on DE:TCE2
David Dai
UBS
UBS
€38.84
Buy
15.86%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Wolfe Research Analyst forecast on DE:TCE2
Andy Chen
Wolfe Research
Wolfe Research
€44.02→€37.97
Buy
13.29%
Upside
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
TD Cowen Analyst forecast on DE:TCE2
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:TCE2
Judah Frommer
Morgan Stanley
Morgan Stanley
€39.7→€43.15
Buy
28.74%
Upside
Assigned
09/10/26
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Celldex (CLDX)
Jefferies Analyst forecast on DE:TCE2
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€58.69
Buy
75.08%
Upside
Reiterated
08/07/26
Celldex (CLDX) Gets a Buy from Jefferies
LifeSci Capital Analyst forecast on DE:TCE2
Sam Slutsky
LifeSci Capital
LifeSci Capital
€48.33
Buy
44.19%
Upside
Reiterated
08/07/26
Barzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target
Barclays Analyst forecast on DE:TCE2
Etzer Darout
Barclays
Barclays
€41.43→€45.74
Buy
36.46%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Buy Rating on Celldex (CLDX)
H.C. Wainwright Analyst forecast on DE:TCE2
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€36.25
Buy
8.14%
Upside
Reiterated
08/07/26
Celldex: Barzo Franchise Momentum and Upcoming Catalysts Support Buy Rating with Unchanged $42 Price Target
Goldman Sachs Analyst forecast on DE:TCE2
Richard Law CFA
Goldman Sachs
Goldman Sachs
€29.34→€32.8
Hold
-2.16%
Downside
Reiterated
08/07/26
Goldman Sachs Reaffirms Their Hold Rating on Celldex (CLDX)
Canaccord Genuity Analyst forecast on DE:TCE2
Edward Nash
Canaccord Genuity
Canaccord Genuity
€51.78
Buy
54.49%
Upside
Reiterated
08/06/26
Celldex: Buy Rating Reaffirmed as Strong 2Q26 Results, Robust Pipeline Support Unchanged $60 Price Target
Guggenheim Analyst forecast on DE:TCE2
Yatin Suneja
Guggenheim
Guggenheim
€86.31
Buy
157.48%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (NASDAQ: XFOR), Celldex (NASDAQ: CLDX) and Climb Bio (NASDAQ: CLYM)
Wells Fargo Analyst forecast on DE:TCE2
Derek Archila
Wells Fargo
Wells Fargo
€6.04→€62.14
Buy
85.38%
Upside
Reiterated
08/06/26
Wells Fargo Reaffirms Their Buy Rating on Celldex (CLDX)
Cantor Fitzgerald Analyst forecast on DE:TCE2
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€52.65
Buy
57.06%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS) and Celldex (NASDAQ: CLDX)
Leerink Partners Analyst forecast on DE:TCE2
Thomas Smith
Leerink Partners
Leerink Partners
€67.32→€60.41
Buy
80.23%
Upside
Reiterated
07/22/26
Celldex price target lowered to $70 from $78 at LeerinkCelldex price target lowered to $70 from $78 at Leerink
Stifel Nicolaus Analyst forecast on DE:TCE2
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€58.69
Buy
75.08%
Upside
Reiterated
07/22/26
Analysts Conflicted on These Healthcare Names: 10x Genomics (NASDAQ: TXG), Celldex (NASDAQ: CLDX) and MaxCyte (NASDAQ: MXCT)
UBS Analyst forecast on DE:TCE2
David Dai
UBS
UBS
€38.84
Buy
15.86%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Wolfe Research Analyst forecast on DE:TCE2
Andy Chen
Wolfe Research
Wolfe Research
€44.02→€37.97
Buy
13.29%
Upside
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
TD Cowen Analyst forecast on DE:TCE2
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
ASNDAscendis Pharma
HROWHarrow Health
IRTCIrhythm Technologies
DNLIDenali Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Celldex

3 Months
Joseph PantginisH.C. Wainwright
Success Rate
11/15 ratings generated profit
73%
Average Return
+5.07%
Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +5.07% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Success Rate
14/15 ratings generated profit
93%
Average Return
+35.79%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +35.79% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
14/15 ratings generated profit
93%
Average Return
+42.36%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +42.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TCE2 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
5
6
14
14
11
Buy
6
9
11
14
10
Hold
2
1
2
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
16
27
30
24
In the current month, TCE2 has received 21 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. TCE2 average Analyst price target in the past 3 months is 53.08.
Each month's total comprises the sum of three months' worth of ratings.

TCE2 Financial Forecast

TCE2 Earnings Forecast

Next quarter’s earnings estimate for TCE2 is -€0.88 with a range of -€0.94 to -€0.81. The previous quarter’s EPS was -€0.81. TCE2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TCE2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for TCE2 is -€0.88 with a range of -€0.94 to -€0.81. The previous quarter’s EPS was -€0.81. TCE2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TCE2 has Performed in-line its overall industry.

TCE2 Sales Forecast

Next quarter’s sales forecast for TCE2 is €622.58K with a range of €0.00 to €2.58M. The previous quarter’s sales results were €18.94K. TCE2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TCE2 has Performed in-line its overall industry.
Next quarter’s sales forecast for TCE2 is €622.58K with a range of €0.00 to €2.58M. The previous quarter’s sales results were €18.94K. TCE2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TCE2 has Performed in-line its overall industry.

TCE2 Stock Forecast FAQ

What is DE:TCE2’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex Therapeutics Inc’s 12-month average price target is 53.08.
    What is DE:TCE2’s upside potential, based on the analysts’ average price target?
    Celldex Therapeutics Inc has 58.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Celldex Therapeutics Inc a Buy, Sell or Hold?
          Celldex Therapeutics Inc has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Celldex Therapeutics Inc’s share price target?
            The average share price target for Celldex Therapeutics Inc is 53.08. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €86.31 ,and the lowest forecast is €32.80. The average share price target represents 58.35% Increase from the current price of €33.52.
              What do analysts say about Celldex Therapeutics Inc?
              Celldex Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Celldex Therapeutics Inc?
                To buy shares of DE:TCE2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.